FUTURE PLANS AND PROSPECTS

See "Business – Our Development Strategies" for a detailed description of our future plans.

[**REDACTED**]

We estimate that we will receive [**REDACTED**] from the [**REDACTED**] of approximately HK$[**REDACTED**] million, after deducting [**REDACTED**], fees and estimated expenses payable by us in connection with the [**REDACTED**], and assuming an [**REDACTED**] of HK$[**REDACTED**] per Share, being the [**REDACTED**] of the indicative [**REDACTED**] range stated in this document. If the [**REDACTED**] is set at HK$[**REDACTED**] per Share, being the high end of the indicative [**REDACTED**] range, the [**REDACTED**] from the [**REDACTED**] will increase by approximately HK$[**REDACTED**] million. If the [**REDACTED**] is set at HK$[**REDACTED**] per Share, being the low end of the indicative [**REDACTED**] range, the [**REDACTED**] from the [**REDACTED**] will decrease by approximately HK$[**REDACTED**] million.

Assuming an [**REDACTED**] at the [**REDACTED**] of the indicative [**REDACTED**] range and that the [**REDACTED**] is not exercised, we currently intend to apply these [**REDACTED**] for the following purposes:

- Approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used for the research, development and commercialization of our Core Products, namely, SKB264 and A166;

  – approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used for SKB264, of which [**REDACTED**]% is expected to be used for clinical trial development and [**REDACTED**]% is expected to be used for commercialization.

    The [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to advance the clinical trials of SKB264 in China, of which:

    (i) [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to fund ongoing and planned clinical trials of SKB264 for TNBC. We commenced patient enrollment for SKB264's pivotal phase 3 trial in August 2022 and anticipate to complete patient enrollment for this pivotal trial in the second half of 2023. We intend to use the results from this trial to support NDA submission to the NMPA by the end of 2023. We also initiated a phase 2 trial in July 2022 to evaluate SKB264 with or without A167 as a first-line treatment for advanced TNBC;

    (ii) [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to fund ongoing and planned clinical trials of SKB264 for NSCLC. We expect to commence a phase 3 trial in the second half of 2023 in EGFR-mutant NSCLC patients who have failed EGFR-TKI therapy. We

intend to use the results from this trial to support NDA submission to the NMPA. We also initiated a phase 2 trial in May 2022 to evaluate SKB264 plus A167 with or without chemotherapy as an early-line treatment for advanced EGFR-wild type and EGFR-mutant NSCLC; and

(iii) [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to fund ongoing and planned clinical trials of SKB264 for HR+/HER2- BC. We expect to complete SKB264's dose expansion study in HR+/HER2- BC patients as part of its global phase 1/2 trial and advance to phase 3 in the second half of 2023. We intend to use the results from this trial to support NDA submission to the NMPA.

For details of SKB264's clinical development plan, see "Business – Our Pipeline – Oncology Franchise – ADCs – SKB264 – Clinical Development Plan".

The [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to prepare for the anticipated commercial launch of SKB264. Subject to regulatory communications and marketing approval, we expect to launch SKB264 in the China market in the second half of 2024 or the first half of 2025. We plan to set up a fully-fledged commercialization team by the end of 2023 to oversee and coordinate the pre-marketing preparation for SKB264.

– approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used for A166, of which [**REDACTED**]% is expected to be used for clinical trial development and [**REDACTED**]% is expected to be used for commercialization.

The [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to advance the clinical trials of A166 in China, of which:

(i) [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to fund ongoing and planned clinical trials of A166 for HER2+ BC. We plan to commence a confirmatory phase 3 trial of A166 as a 2L+ treatment for advanced HER2+ BC in the second half of 2023, pending consultation with the CDE; and

(ii) [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used to fund ongoing and planned clinical trials of A166 for HER2+ GC. We expect to conclude A166's phase 1b trial in advanced HER2+ GC patients in the first half of 2024.

For details of A166's clinical development plan, For details, see "Business – Our Pipeline – Oncology Franchise – ADCs – A166 – Clinical Development Plan";

The [**REDACTED**]%, or HK$[**REDACTED**] million, is expected to be used for the preparation for the anticipated commercial launch of A166. Subject to regulatory communications and marketing approval, we expect to launch A166 in the China market in the second half of 2024 or the first half of 2025. We plan to set up a fully-fledged commercialization team by the end of 2023 to oversee and coordinate the pre-marketing preparation for A166.

- Approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used for the research, development and commercialization of our other key products, including:

  – approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to fund the clinical development and preparation for NDA submission and anticipated commercialization of A140, including our ongoing pivotal phase 3 clinical trial for RAS wild-type mCRC, which we plan to complete primary analysis and file an NDA in the second half of 2023;

  – approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to fund the clinical development and anticipated commercialization of A167, including a phase 3 trial of A167 in combination with chemotherapy for RM-NPC with ongoing patient enrollment, as well as two ongoing phase 2 trials in combination with SKB264 for NSCLC and TNBC, respectively. See "Business – Our Pipeline – Oncology Franchise – Other Modalities – A167 – Clinical Development Plan";

  – approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to fund the clinical development of A400, including its ongoing phase 1/2 clinical trial for advanced RET+ solid tumors and pivotal trial for 2L+ advanced RET+ NSCLC, as well as a planned pivotal trial for 1L advanced RET+ NSCLC that we anticipate to commence in the second half of 2023 and a pivotal trial anticipated to commence in the first half of 2024 for advanced RET+ MTC, and a planned phase 2 trial for adjuvant or neoadjuvant RET+ NSCLC. See "Business – Our Pipeline – Oncology Franchise – Other Modalities – A400 – Clinical Development Plan";

  – approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to fund the clinical development of A223, including an ongoing phase 2 trial for severe AA and a planned pivotal phase 3 trial in the second half of 2023 for moderate-to-severe RA. See "Business – Our Pipeline – Non-oncology Franchise – A223 – Clinical Development Plan";

- Approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to fund the continued development of our technology platforms, advance our other existing pipeline assets, and explore and develop new drug candidates:

  – approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to further develop our ADC, biologics and small molecule platforms. See "Business – Our Technology Platforms."

  – approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to expand our existing pipeline, of which approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to fund the research and development of other existing non-key products, and approximately [**REDACTED**]%, or HK$[**REDACTED**] million will be used to explore and develop new products.

- Approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used to fund the expansion of our manufacturing capabilities and quality control system to support the anticipated commercialization of our late-stage assets. For instance, over the next few years, we plan to install one additional 2,000 L single-use bioreactor, bringing our total in-house capacity to 6,000 L. In addition, we plan to upgrade and improve our quality control system covering all major aspects of our operation, from R&D, procurement and supply chain to manufacturing. We will aim to adopt the latest and highest international standards used by pharmaceutical MNCs; and

- Approximately [**REDACTED**]%, or HK$[**REDACTED**] million, will be used for working capital and other general corporate purposes.

The above [**REDACTED**] of the [**REDACTED**] from the [**REDACTED**] will be adjusted on a pro rata basis in the event that the [**REDACTED**] is fixed at a higher or lower level compared to the [**REDACTED**] of the indicative [**REDACTED**] range stated in this document.

If the [**REDACTED**] is exercised in full, the [**REDACTED**] that we will receive will be approximately HK$[**REDACTED**] million, assuming an [**REDACTED**] of HK$[**REDACTED**] per Share (being the [**REDACTED**] of the indicative [**REDACTED**] range). In the event that the [**REDACTED**] is exercised in full, we intent to apply the additional [**REDACTED**] to the above purposes in the proportions stated above.

To the extent that the [**REDACTED**] from the [**REDACTED**] are not immediately used for the purposes described above and to the extent permitted by the relevant laws and regulations, they will be placed in short-term demand deposits with authorized and licensed commercial banks or financial institutions (as defined under the Securities and Futures Ordinance).

We will issue an appropriate announcement if there is any material change to the above proposed [**REDACTED**].